Epidemiological factors associated with ESBL- and non ESBL-producingE. colicausing urinary tract infection in general practice

Urinary tract infections due to extended-spectrum beta-lactamase-producing Gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary referral hospital

(2015) Michael Osthoff et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Community-Onset Escherichia coli Infection Resistant to Expanded-Spectrum Cephalosporins in Low-Prevalence Countries

(2014) Benjamin A. Rogers et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Service evaluation of selected risk factors for extended-spectrum beta-lactamase Escherichia coli urinary tract infections: a case–control study

(2014) T. Inns et al.   JOURNAL OF HOSPITAL INFECTION

Characterization of Third-Generation Cephalosporin-Resistant Escherichia coli from Bloodstream Infections in Denmark

(2014) Frank Hansen et al.   Microbial Drug Resistance

High prevalence of faecal carriage of ESBL-producing Enterobacteriaceae in Norwegian patients with gastroenteritis

(2014) Silje Bakken Jørgensen et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Epidemiology and Risk Factors for Isolation of Escherichia coli Producing CTX-M-Type Extended-Spectrum β-Lactamase in a Large U.S. Medical Center

(2013) Kayoko Hayakawa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections

(2013) F. Jansaker et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization?

(2013) T. Goulenok et al.   JOURNAL OF HOSPITAL INFECTION

Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae –A Case–Control Study in a Low Prevalence Country

(2013) Arne Søraas et al.   PLoS One

Editorial Commentary: Extended-Spectrum  -Lactamase-Producing Escherichia coli in the United States: Time to Rethink Empirical Treatment for Suspected E. coli Infections?

(2012) B. Foxman   CLINICAL INFECTIOUS DISEASES

Community-Associated Extended-Spectrum β-Lactamase–Producing Escherichia coli Infection in the United States

(2012) Yohei Doi et al.   CLINICAL INFECTIOUS DISEASES

Molecular Epidemiology over an 11-Year Period (2000 to 2010) of Extended-Spectrum  -Lactamase-Producing Escherichia coli Causing Bacteremia in a Centralized Canadian Region

(2011) G. Peirano et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Treatment with Fluoroquinolones or with  -Lactam- -Lactamase Inhibitor Combinations Is a Risk Factor for Isolation of Extended-Spectrum- -Lactamase-Producing Klebsiella Species in Hospitalized Patients

(2010) K. M. Wener et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Implications, Risk Factors and Mortality Following Community-onset Bacteremia Caused by Extended-spectrum β-lactamase (ESBL) and non-ESBL Producing Escherichia coli

(2010) Chia-Jung Hsieh et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

A Multinational Survey of Risk Factors for Infection with Extended‐Spectrum β‐Lactamase–Producing Enterobacteriaceae in Nonhospitalized Patients

(2009) Ronen Ben‐Ami et al.   CLINICAL INFECTIOUS DISEASES

Evaluation of detection of extended-spectrum beta-lactamases among Escherichia coli and Klebsiella spp. isolates by VITEK 2 AST-N029 compared to the agar dilution and disk diffusion methods

(2008) Sofia D. Nyberg et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES